News

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and ...

Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Bristol-Myers Squibb shares snapped six-session losing streak

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

Bristol Myers, Bain Capital form new company to develop immunology drugs

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
BioPharma Dive4d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

Bristol Myers drug fails main goal in cancer-linked anemia trial

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main goal of a late-stage trial to treat anemia caused by a rare bone marrow ...